

Press Release

Biofrontera to Present at the 18th Annual Rodman & Renshaw Global Investment Conference

Leverkusen, Germany, August 29, 2016 – Biofrontera AG (FSE: B8F), the specialist for the treatment of sun-induced skin cancer, today announced that it will be featured as a presenting company at the 18th Annual Rodman & Renshaw Global Investment Conference, being held on September 11-13, 2016 at The Lotte New York Palace Hotel in New York City.

Dr. Hermann Lübbert, Biofrontera's Chief Executive Officer, will provide an overview of the Company's business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

If you are an institutional investor, and would like to attend the Company's presentation, please click on the link (www.rodmanevents.com) to register for the conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.

Details for the presentation are as follows:

Date: Tuesday, September 13, 2016

Time: 9:10AM EST

Room: Kennedy I Floor 4

The presentation will be webcast live. To access the webcast, please visit <http://wsw.com/webcast/rrshq26/b8f.de>. The webcast replay will remain available for 90 days following the live presentation.

-Ends-

Enquiries, please contact: Biofrontera AG

Thomas Schaffer, Chief Financial Officer

+49 (0) 214 87 63 2 0

press@biofrontera.com

IR Germany: Brainwell Asset Solutions

Jürgen Benker

+49 (0) 152 08931514

IR UK: Seton Services

Toni Vallen

+44(0) 20 7729 0805

IR and PR US: The Ruth Group

IR: Lee Roth / Tram Bui

+1 646-536-7012 / 7035

PR: Kirsten Thomas

+1 508-280-6592

Press release

About Biofrontera

Biofrontera Group (FSE: B8F, ISIN DE0006046113) **Biofrontera** is a biopharmaceutical company specializing in the development, sale and distribution of drugs, medical devices and medical cosmetics for the care and treatment of skin diseases. Biofrontera's most important product is Ameluz®, a prescription drug which was initially approved and marketed in Europe and is now also approved in the US for the treatment of mild and moderate actinic keratosis, a precursor to squamous cell carcinoma, with photodynamic therapy (light therapy). Biofrontera is the first German pharmaceutical start-up company to obtain centralized EU and now US approval for a medical device/drug it has developed itself.

The company also markets the Belixos® dermatological range of cosmetics. Belixos® products, a cream, a gel, a scalp tonic and acute roll-on, contain combinations of active substances extracted from plants, relieve itching and redness and are used for the regenerative care of chronic skin conditions such as atopic dermatitis or psoriasis. The Belixos® Protect, a daily skincare for sun-damaged skin, complements this dermo-cosmetic line. All products are available through Amazon.

The Biofrontera Group was established in 1997 by Prof. Dr Hermann Lübbert, the Chairman of the company's Management Board, and has its headquarters in Leverkusen, Germany.

For more information, visit www.biofrontera.com

This communication expressly or implicitly contains certain forward-looking statements concerning the business activities of Biofrontera AG. These forward-looking statements reflect the opinion of Biofrontera at the time of this communication and involve certain known and unknown risks. The actual results achieved by Biofrontera may differ significantly from future results or performances which are published in its forward-looking statements. Biofrontera assumes no responsibility to update its forward-looking statements.